Acute-care hospital reencounters in COVID-19 patients
- PMID: 34019232
- PMCID: PMC8138514
- DOI: 10.1007/s11357-021-00378-2
Acute-care hospital reencounters in COVID-19 patients
Abstract
Acute-care hospital reencounters (ACHEs)-encompassing emergency department visits, observation stays, and hospital readmissions-following COVID-19 hospitalization may exacerbate health care system strain and impair recovery from illness. We sought to characterize these reencounters and factors associated with reencounters. We identified the first consecutive 509 patients hospitalized for COVID-19 within an IL hospital network, and examined ACHEs, experienced within 30 days and 4 months of index hospitalization. We identified independent predictors of reencounter using binary logistic regression. Of 509 patients, 466 (91.6%) were discharged alive from index COVID-19 hospitalization. Within 30 days and 4 months, 12.4% and 21.5% of patients, respectively, experienced ACHEs. The median time to first ACHE was 24.2 (IQR 6.5, 55) days. COVID-19 symptom exacerbation was the leading reason for early ACHE (44.8%). Reencounters, both within 30 days and 4 months, were associated with a history of a neurological disorder before COVID-19 (OR 2.78 [95% CI 1.53, 5.03] and OR 2.75 [95% CI 1.67, 4.53], respectively). Older patients and those with diabetes mellitus, chronic obstructive pulmonary disease, or organ transplantation tended towards more frequent ACHEs. Steroid treatment during COVID-19 hospitalization demonstrated reduced odds of 30-day reencounter (OR 0.31 [95% CI 0.091, 0.79]). Forty-nine patients had repeat SARS-CoV-2 nasopharyngeal testing during a reencounter; twelve (24.5%) patients had positive reencounter tests and experienced more frequent reencounters than those testing negative. COVID-19 symptom exacerbation is a leading cause of early ACHE after COVID-19 hospitalization, and steroid use during index hospitalization may reduce early reencounters. Neurologic illness before COVID-19 predicts ACHEs.
Keywords: COVID-19; Post-hospital syndrome; Post-viral syndrome; Readmission; Reencounter.
© 2021. American Aging Association.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775. JAMA. 2020. PMID: 32320003 Free PMC article.
-
History repeats itself: Impact of mental illness on violent reinjury and hospital reencounters among female victims of interpersonal violence.J Trauma Acute Care Surg. 2023 Jul 1;95(1):143-150. doi: 10.1097/TA.0000000000003984. Epub 2023 Apr 17. J Trauma Acute Care Surg. 2023. PMID: 37068014 Free PMC article.
-
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394. JAMA. 2020. PMID: 32250385 Free PMC article.
-
Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.Sci Total Environ. 2020 Aug 1;728:138812. doi: 10.1016/j.scitotenv.2020.138812. Epub 2020 Apr 22. Sci Total Environ. 2020. PMID: 32335406 Free PMC article.
-
Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission - United States, March-August 2020.MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1695-1699. doi: 10.15585/mmwr.mm6945e2. MMWR Morb Mortal Wkly Rep. 2020. PMID: 33180754 Free PMC article.
Cited by
-
Impact of healthcare system strain on the implementation of ICU sedation practices and encephalopathy burden during the early COVID-19 pandemic.Geroscience. 2024 Sep 7. doi: 10.1007/s11357-024-01336-4. Online ahead of print. Geroscience. 2024. PMID: 39243283
-
Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17.Molecules. 2022 Dec 19;27(24):9044. doi: 10.3390/molecules27249044. Molecules. 2022. PMID: 36558177 Free PMC article.
-
Readmission Risk after COVID-19 Hospitalization: A Moderation Analysis by Vital Signs.South Med J. 2022 Nov;115(11):842-848. doi: 10.14423/SMJ.0000000000001472. South Med J. 2022. PMID: 36318952 Free PMC article.
-
Pulmonary Complications after COVID-19.Life (Basel). 2022 Feb 28;12(3):357. doi: 10.3390/life12030357. Life (Basel). 2022. PMID: 35330108 Free PMC article.
-
Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality.JAMA Netw Open. 2022 Mar 1;5(3):e221455. doi: 10.1001/jamanetworkopen.2022.1455. JAMA Netw Open. 2022. PMID: 35258575 Free PMC article.
References
-
- WHO Coronavirus Disease (COVID-19) Dashboard. 2020. Accessed 2/24/2021, 2020, at https://covid19.who.int/
-
- COVIDView: a weekly surveillance summary of U.S. COVID-19 activity. 2020. Accessed 11/23/2020, at https://www.cdc.gov/coronavirus/2019-ncov/covid-data/pdf/covidview-11-20...
-
- Wadhera RK, Joynt Maddox KE, Kazi DS, Shen C, Yeh RW. Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis. BMJ. 2019;366:l4563. doi: 10.1136/bmj.l4563. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous